Clearly, no single pathway accounts for all the effects of obesity on cancer prognosis, because illustrated from the metabolic syndrome discussion. cancer stem cells in the response to energy balance modulation, and growing pharmacologic methods that target energy balancerelated pathways. == Intro == Obesity is an founded epidemiologic risk element for a broad spectrum of cancers; it also negatively affects prognosis for many but not all types of cancer.14Although the prevalence of obesity has risen steadily for the past several decades in the United States and many other countries,5,6the mechanisms underlying the poorer outcomes in many obese patients with cancer and cancer survivors are complex and may include GSK3532795 obesity-mediated effects on cancer-related processes such as tumor progression; problems associated with adjusting dose of cancer therapeutics in obese individuals; and/or additional comorbid conditions associated with weight problems such as diabetes, cardiovascular disease, and thromboembolic conditions. Significant evidence suggests that although these factors may influence survival, a number of energy balancerelated sponsor factors clearly impact tumor progression and/or treatment responsiveness after cancer develops. Hormones along with other sponsor factors regulate many energy balancerelated physiologic processes, including hunger, energy expenditure, body temperature control, and nutrient and energy metabolism.7Recent findings, particularly from animal models of cancer progression in which specific pathways have been modified, provide evidence that important host factors associated with Mouse monoclonal to ABCG2 metabolic syndrome link energy balance to cancer progression and/or responsiveness to therapy.7This mechanistic GSK3532795 review focuses on these host factors, including leptin, adiponectin, steroid hormones, reactive oxygen species associated with inflammatory processes, insulin, insulin-like growth factor1 (IGF-1), and sirtuins. Content articles with this review were identified using a MEDLINE database search (from September 1, 1969, to September 1, 2009) for the keywords cancer OR carcinogenesis AND progression OR prognosis AND weight problems OR energy balance. == LEPTIN == The peptide hormone leptin is definitely secreted from adipocytes and involved in hunger control and energy metabolism through its effects within the hypothalamus.8High circulating levels of leptin are characteristic of an obese state. Leptin resistance explains the inability of exogenous leptin administration to prevent weight gain.9Epidemiologic studies suggest an association GSK3532795 between circulating leptin levels and cancer progression, with the strongest links shown in colon, prostate, and breast cancers.1012As exhibited in in vitro studies, leptin stimulates preneoplastic and neoplastic colon cell proliferation without inducing normal cell proliferation.13Leptin also promotes proliferation in some (but certainly not all) mammary along with other cancer cell lines in vitro and promotes tumor invasion and angiogenesis in some (but not all) animal models.14,15 Although not well analyzed, and with some inconsistency across model systems, leptin remains positioned as an important component in the association between energy balance and cancer. It communicates the size of fat stores to the CNS, because levels of leptin and adipose cells strongly correlate in animals and humans.8The Janus kinase 2/signal transducer and activator of transcription 3 pathway transduces the signal of leptin from its receptor.16,17There is emerging evidence of crosstalk between the Janus kinase/signal transducer and activator of transcription family of transcription factors, the insulin/IGF-1/Akt pathway, and adenosine monophosphateactivated protein kinase (AMPK).18In addition, leptin production and hepatic IGF-1 synthesis may be coregulated at the level of the hypothalamus/pituitary/adrenal axis.16Leptin also functions as an adipocytokine and may influence inflammatory responses, possibly by triggering launch of interleukin (IL) -6 along with other obesity-related cytokines.16,17 == ADIPONECTIN == The peptide hormone adiponectin is produced by adipocytes and involved in the regulation of carbohydrate and lipid metabolism and insulin level of sensitivity.19Plasma levels of adiponectin, in contrast with additional adipokines, are decreased in response to several metabolic impairments, including type 2 diabetes, dyslipidemia, and intense obesity.19Lower levels of adiponectin are consistently related to increased risk of multiple malignancies, including uterine,20postmenopausal breast,21colorectal,22and higher-grade prostate tumors.23This association may be explained by the observation that adiponectin downregulates several growth-promoting pathways,19,24,25and decreased adiponectin may have a permissive effect on tumor growth. The obesity-related decrease in adiponectin can be partially reversed by weight loss, although.
Nucleoside Transporters